Company / SG&A Expense
Lilly (Eli) SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$11.1B
FY2025
5-year range
$6.1B / $11.1B
FY2021-FY2025
Trend
+29.1%
vs FY2024
Sector context
#4 of 213
Health Care
What the data says
Among 213 Health Care companies, Lilly (Eli) is in the bottom 2% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $6.1B in FY2022 to $11.1B in FY2025.
Based on SEC 10-K filings.
$11.1B in FY2025 with a 5-year CAGR of +13.2%. Top quartile in the Health Care sector.
Increased from $6.4B to $11.1B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +21.9%
- 5-Year CAGR
- +13.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 213This company $11.1B Sector average $722.3M
▼
+1435.9% above sector average
Key checks
Key Insights
- Lilly (Eli)'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +13.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 29.1% year-over-year.
- Ranks #4 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.1B | +29.1% |
| FY2024 | $8.6B | +33.6% |
| FY2023 | $6.4B | +5.1% |
| FY2022 | $6.1B | -1.5% |
| FY2021 | $6.2B | +4.0% |
| FY2020 | $6.0B | -3.8% |
| FY2019 | $6.2B | +4.0% |
| FY2018 | $6.0B | -8.5% |
| FY2017 | $6.5B | +0.1% |
| FY2016 | $6.5B | -0.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026